Scientists probe Ketamine's Fast-Acting depression relief in brain receptor study
NCT ID NCT03973268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how ketamine, a fast-acting antidepressant, affects the brain. Researchers want to understand if a specific brain receptor (AMPA) is key to its effects. Seventy adults with treatment-resistant depression will take part, receiving ketamine and a drug that blocks AMPA receptors to see how their mood and brain activity change.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Can a structured care pathway ease teen depression?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can a nasal spray break through tough depression?